Sarcoma News

A trial assessing NBTXR3 plus radiotherapy met its primary endpoint of improved pathologic complete response rate compared with standard of care among patients with soft tissue sarcoma, according to the agent’s manufacturer.

Although a risk assessment tool can identify patients with cancer who are at risk for hepatitis B virus (HBV) reactivation from anticancer therapy, most patients will still require HBV testing, according to study results.

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

Both anthracycline- and gemcitabine-based treatment regimens appeared moderately active in epithelioid sarcoma, according to a brief report published in JAMA Oncology.

CHICAGO — The receptor tyrosine kinase inhibitor anlotinib extended PFS and showed greater antitumor activity compared with placebo among patients with soft tissue sarcoma who regressed on or were intolerant to anthracycline-based chemotherapy, according to data presented at the ASCO Annual Meeting

CHICAGO — Pexidartinib showed significant antitumor activity among patients with tenosynovial giant cell tumors compared with placebo, according to results of the ENLIVEN trial presented at the ASCO Annual Meeting.

CHICAGO — Maintenance chemotherapy after standard intensive therapy improved DFS and OS rates among children with rhabdomyosarcoma, according to study results presented during the plenary session of the ASCO Annual Meeting.

CHICAGO — Microsatellite instability-high tumors predicted occurrence of Lynch syndrome across various cancer types, not just cancers commonly known to be associated with the disease, according to study results presented at ASCO Annual Meeting.

CHICAGO — Use of geriatric assessment during routine care of older individuals with advanced cancer significantly improved physician-patient communication about age-related concerns, according to randomized study results presented at ASCO Annual Meeting.

Researchers identified chromatin entropy nuclei as a prognostic marker for patients with uterine sarcomas, ovarian carcinomas and endometrial carcinomas, according to published findings.